$Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial$
QR Code

Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial

Background The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue accumulation, coronary microcirculatory rarefaction, myocardial fibrosis and vascular stiffness; the resulting impairment of l...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of heart failure Vol. 21; no. 10; pp. 1279 - 1287
Main Authors:	Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos S., Jamal, Waheed, Salsali, Afshin, Schnee, Janet, Kimura, Karen, Zeller, Cordula, George, Jyothis, Brueckmann, Martina, Zannad, Faiez, Packer, Milton, Perrone, Sergio, Nicholls, Stephen, Janssens, Stefan, Bocchi, Edmar, Giannetti, Nadia, Verma, Subodh, Jian, Zhang, Gomez Mesa, Juan Esteban, Spinar, Jindrich, Böhm, Michael, Merkely, Bela, Chopra, Vijay, Senni, Michele, Taddi, Stefano, Tsutsui, Hiroyuki, Chuquiure, Eduardo, La Rocca, Hans Pieter Brunner, Ponikowski, Piotr, Vinereanu, Dragos, Sim, David, Choi, Dong‐Ju, Juanatey, Jose Ramon Gonzalez, Squire, Iain, Januzzi, James, Pina, Ileana, Pocock, Stuart J., Carson, Peter, Doehner, Wolfram, Miller, Alan, Haas, Markus, Pehrson, Steen, Komajda, Michel, Anand, Inder, Teerlink, John, Rabinstein, Alejandro, Steiner, Thorsten, Kamel, Hooman, Tsivgoulis, Georgios, Lewis, James, Freston, James, Kaplowitz, Neil, Mann, Johannes, Petrie, Mark, Bernstein, Richard, Cheung, Alfred, Green, Jennifer, Kaul, Sanjay, Ping, Carolyn Lam Su, Lip, Gregory, Marx, Nikolaus, McCullough, Peter, Mehta, Cyrus, Rosenstock, Julio, Sattar, Naveed, Scirica, Benjamin, Wanner, Christoph, Welty, Francine K., Parhofer, Klaus G., Clayton, Tim, Pedersen, Terje R., Lees, Kennedy R., Konstam, Marvin A., Greenberg, Barry, Palmer, Mike
Format:	Journal Article
Language:	English
Published:	Oxford, UK John Wiley & Sons, Ltd 01-10-2019 European Society of Cardiology (Wiley)
Subjects:	Cardiology and cardiovascular system Diabetes Heart failure Human health and pathology Life Sciences SGLT2 inhibitors Trial design Heart failure Diabetes Trial design SGLT2 inhibitors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue accumulation, coronary microcirculatory rarefaction, myocardial fibrosis and vascular stiffness; the resulting impairment of left ventricular and aortic distensibility (especially when accompanied by impaired glomerular function and sodium retention) causes increases in cardiac filling pressures and exertional dyspnoea despite the relative preservation of left ventricular ejection fraction. Independently of their actions on blood glucose, sodium–glucose co‐transporter 2 (SGLT2) inhibitors exert a broad range of biological effects (including actions to inhibit cardiac inflammation and fibrosis, antagonize sodium retention and improve glomerular function) that can ameliorate the pathophysiological derangements in HFpEF. Such SGLT2 inhibitors exert favourable effects in experimental models of HFpEF and have been found in large‐scale trials to reduce the risk for serious heart failure events in patients with type 2 diabetes, many of whom were retrospectively identified as having HFpEF. Study design The EMPEROR‐Preserved Trial is enrolling ≈5750 patients with HFpEF (ejection fraction >40%), with and without type 2 diabetes, who are randomized to receive placebo or empagliflozin 10 mg/day, which is added to all appropriate treatments for HFpEF and co‐morbidities. Study aims The primary endpoint is the time‐to‐first‐event analysis of the combined risk for cardiovascular death or hospitalization for heart failure. The trial will also evaluate the effects of empagliflozin on renal function, cardiovascular death, all‐cause mortality and recurrent hospitalization events, and will assess a wide range of biomarkers that reflect important pathophysiological mechanisms that may drive the evolution of HFpEF. The EMPEROR‐Preserved Trial is well positioned to determine if empagliflozin can have a meaningful impact on the course of HFpEF, a disorder for which there are currently few therapeutic options.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23
ISSN:	1388-9842 1879-0844
DOI:	10.1002/ejhf.1596